Pulse Biosciences(PLSE) - 2024 Q2 - Quarterly Results

Financial Performance - Pulse Biosciences, Inc. reported financial results for the fiscal quarter ended June 30, 2024, with a focus on operational performance[4]. - The financial report and operational results are intended to provide insights into the company's performance and future outlook[4]. Board of Directors and Governance - The company appointed Paul A. LaViolette to its Board of Directors, who brings 40 years of experience in global medical technology[5]. - The Board established a new Strategic Advisory Committee to oversee corporate initiatives, including financing and licensing opportunities[5]. - Non-employee directors will receive an annual retainer of $55,000, with additional compensation for committee service, totaling up to$80,000 for the Lead Independent Director[8]. - The company amended its Non-Employee Director Compensation Policy to increase cash compensation for board service[8]. Stock Options and Compensation - Mr. LaViolette received an initial stock option grant to purchase 50,000 shares at a strike price of $15.65, vesting over three years[7]. - Newly appointed members of the Strategic Advisory Committee received 200,000 shares each, vesting over four years[10]. Strategic Initiatives - The company is focused on evaluating financing, partnering, and licensing opportunities as part of its strategic initiatives[5]. - The press release dated August 12, 2024, includes a business update and quarterly results[12].